Technology Introduction:
Our team is developing an innovative targeted cancer therapy against methylation modifications on the tyrosine kinase epidermal growth factor receptor (EGFR). Methylation of two arginine residues in the extracellular domain of EGFR enhances ligand binding and oncogenic signaling. We have developed antibody-drug conjugates (ADCs) that specifically target methylated EGFR, aiming to establish a first-in-class therapeutic strategy for triple-negative breast cancer and other solid tumors.
Industry Applicability:
The RAMeE platform specifically recognizes methylated EGFR (meEGFR), a novel key antigen with tumor-promoting function. Analysis of clinical tumor samples suggests its strong prognostic and predictive value. We are actively developing antibody-drug conjugates (ADCs) and CAR-NK cell therapies targeting meEGFR. This technology shows great promise for commercialization and offers a feasible path toward first-in-class drug development and precision oncology applications targeting difficult cancers.